



I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Box AF, Commissioner of Patents and Trademarks, Washington, DC 20231.

8/8/02
Date

Judith Davies
Judith Davies

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yuqiu Jiang, et al.
Application No. : 09/551,621
Filed : April 17, 2000
For : COMPOSITIONS FOR THE TREATMENT AND
DIAGNOSIS OF BREAST CANCER AND METHODS FOR
THEIR USE
Examiner Janet L. Epps
Art Unit 1635
Docket No. 210121.470C5

DECLARATION OF SUSAN HARLOCKER, PH.D.

Considered
12-9-02

Box AF
Commissioner of Patents
Washington D.C. 20231

JE

The undersigned, Susan Harlocker, Ph.D., hereby declares:

1. I am a Scientist at Corixa Corporation, the assignee of the subject application. The following experiments were performed under my supervision.

2. MRNA EXPRESSION ANALYSIS OF B726P USING QUANTITATIVE REAL-TIME PCR:

The mRNA expression pattern for B726P, in particular, the isoform referred to as the combined ORF of B726P, (polynucleotide sequence set forth in SEQ ID NO:474) was examined using quantitative real-time PCR. Expression levels were

determined in a large panel of breast cancer tissues including primary and metastatic tumors, as well as a wide variety of normal tissues including, uterus, activated PBMC, resting PBMC, pancreas, liver, colon, spleen, esophagus, thyroid gland, spinal cord, bone, thymus, cartilage, lung, trachea, adrenal gland, bone marrow, brain, sm. intestine, stomach, heart, kidney, prostate, pituitary, skin, skeletal muscle, ovary, retina, salivary gland, ureter, and vena cava. As shown in Figure 1, B726P combined ORF was found to be greatly over-expressed in 30% of breast tumor tissues tested (8/27) compared to all normal tissue samples tested. As Figure 1 shows, the average over-expression of this gene in the 30% of breast tumor samples was about 12,500 copies per 1000 pg actin as compared to an average of 390 copies per 1000 pg actin in normal breast and 0 copies per 1000 pg actin observed in normal tissues.

4. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful, false statements, and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Susan L Harlocker
Susan Harlocker, Ph.D.

8/7/02
Date

B726P Combined ORF (SEQ ID NO:474) Extended Breast Panel

